The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
The company posted net profit of Rs.34.24 crores for the period ended June 30, 2020.
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Board declares interim dividend of Rs 2 per equity share
The company expects revenue growth of 10-15 per cent in the US
Subscribe To Our Newsletter & Stay Updated
